Chromadex (CDXC) and The Competition Head-To-Head Survey

Chromadex (NASDAQ: CDXC) is one of 187 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare Chromadex to related companies based on the strength of its profitability, earnings, analyst recommendations, risk, dividends, valuation and institutional ownership.

Profitability

This table compares Chromadex and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Chromadex -21.89% -47.30% -32.25%
Chromadex Competitors -4,574.20% -472.25% -40.09%

Volatility and Risk

Chromadex has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, Chromadex’s peers have a beta of 1.55, meaning that their average stock price is 55% more volatile than the S&P 500.

Valuation & Earnings

This table compares Chromadex and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Chromadex $26.81 million -$2.92 million -43.57
Chromadex Competitors $217.36 million -$39.57 million -59.15

Chromadex’s peers have higher revenue, but lower earnings than Chromadex. Chromadex is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings for Chromadex and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chromadex 0 0 3 0 3.00
Chromadex Competitors 547 2500 6703 131 2.65

Chromadex currently has a consensus price target of $7.00, indicating a potential upside of 14.75%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.14%. Given Chromadex’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Chromadex is more favorable than its peers.

Institutional & Insider Ownership

6.1% of Chromadex shares are held by institutional investors. Comparatively, 49.9% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 11.6% of Chromadex shares are held by company insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Chromadex beats its peers on 8 of the 13 factors compared.

About Chromadex

Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply